NASDAQ:ALLO Allogene Therapeutics - ALLO Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Allogene Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. $7.20 -0.52 (-6.74%) (As of 02/8/2023 12:00 AM ET) Add Compare Share Share Today's Range$7.19▼$7.7550-Day Range$5.62▼$9.4652-Week Range$5.41▼$17.49Volume1.28 million shsAverage Volume1.86 million shsMarket Capitalization$1.04 billionP/E RatioN/ADividend YieldN/APrice Target$20.27 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Allogene Therapeutics MarketRank™ ForecastAnalyst RatingModerate Buy2.73 Rating ScoreUpside/Downside181.6% Upside$20.27 Price TargetShort InterestBearish42.68% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.13Based on 3 Articles This WeekInsider TradingSelling Shares$63,303 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.38) to ($2.83) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.23 out of 5 starsMedical Sector317th out of 1,026 stocksBiological Products, Except Diagnostic Industry56th out of 167 stocks 4.4 Analyst's Opinion Consensus RatingAllogene Therapeutics has received a consensus rating of Buy. The company's average rating score is 2.73, and is based on 9 buy ratings, 1 hold rating, and 1 sell rating.Price Target Upside/DownsideAccording to analysts' consensus price target of $20.27, Allogene Therapeutics has a forecasted upside of 181.6% from its current price of $7.20.Amount of Analyst CoverageAllogene Therapeutics has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock. Previous Next 0.0 Short Interest Percentage of Shares Shorted42.68% of the float of Allogene Therapeutics has been sold short.Short Interest Ratio / Days to CoverAllogene Therapeutics has a short interest ratio ("days to cover") of 18.1, which indicates bearish sentiment.Change versus previous monthShort interest in Allogene Therapeutics has recently increased by 2.18%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldAllogene Therapeutics does not currently pay a dividend.Dividend GrowthAllogene Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ALLO. Previous Next 2.9 News and Social Media Coverage News SentimentAllogene Therapeutics has a news sentiment score of 0.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Allogene Therapeutics this week, compared to 1 article on an average week.Search Interest18 people have searched for ALLO on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat Follows4 people have added Allogene Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Allogene Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $63,303.00 in company stock.Percentage Held by Insiders29.80% of the stock of Allogene Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.94% of the stock of Allogene Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Allogene Therapeutics are expected to decrease in the coming year, from ($2.38) to ($2.83) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Allogene Therapeutics is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Allogene Therapeutics is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAllogene Therapeutics has a P/B Ratio of 1.12. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Allogene Therapeutics (NASDAQ:ALLO) StockAllogene Therapeutics, Inc. operates as a clinical stage immuno-oncology company pioneering the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer. The firm develops a pipeline of off-the-shelf T cell product candidates that are designed to target and kill cancer cells. Its engineered T cells are allogeneic, which are derived from healthy donors for intended use in any patient. The company was founded by Arie S. Belldegrun, David D. Chang, David M. Tanen, and Joshua A. Kazam in November 2017 and is headquartered in South San Francisco, CA.Read More Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Stock News HeadlinesFebruary 3, 2023 | finance.yahoo.com4 Biotech Stocks Set to Outpace Q4 Earnings EstimatesFebruary 1, 2023 | wsj.comAllogene Therapeutics Presents Data on Dagger(TM), a Next Generation AlloCAR T(TM) Platform TechnologyFebruary 8, 2023 | Vector Vest (Ad)Free Stock Analysis Report: See the Right Way to Analyze StocksGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. February 1, 2023 | finance.yahoo.comAllogene Therapeutics Presents Data on Dagger™, a Next Generation AlloCAR T™ Platform TechnologyJanuary 24, 2023 | msn.comAllogene stock rises ~15% as JPMorgan upgrades on near-term catalystsJanuary 24, 2023 | marketwatch.comAllogene Therapeutics Shares Up 13% on Publication of ALLO-715 Trial DataJanuary 24, 2023 | cnbc.comJPMorgan says this biotech stock could rally 60%January 24, 2023 | markets.businessinsider.com5 Analysts Have This to Say About Allogene TherapeuticsFebruary 8, 2023 | Vector Vest (Ad)Free Stock Analysis Report: See the Right Way to Analyze StocksGet a full report that tells you what a stock is really worth, how safe the stock is, and if the timing is right to buy the stock. Plus a definitive Buy, Sell, Hold recommendation. January 24, 2023 | finance.yahoo.comAllogene Therapeutics Announces Publication in Nature Medicine of Data from its Phase 1 UNIVERSAL Study of ALLO-715 for the Treatment of Relapsed/Refractory Multiple MyelomaJanuary 20, 2023 | marketwatch.comCAR T-Cell Therapy Market Size and Share Research Report 2023 by Top Key Players, Types, Applications, Growth Rate and Forecast to 2029January 17, 2023 | finance.yahoo.comAllogene Therapeutics Announces Participation in Two Upcoming Investor ConferencesJanuary 12, 2023 | marketwatch.comCAR T-Cell Therapy Agents Market 2023 : Growth Analysis, Key Stakeholders, Regional Outlook, End-User Applicants by 2029January 11, 2023 | marketwatch.comDrug based on CAR T-Cell Market 2023 Expected to Witness the Highest Revenue Growth Over Forecast to 2029January 4, 2023 | finance.yahoo.comAllogene Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare ConferenceDecember 23, 2022 | marketwatch.comImmuno-oncology Therapy Market Growth and Global Share 2023 | Developing Regions, Emerging Trends and Industry Size Forecast to 2029December 21, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Universal Health (UHS), Albireo Pharma (ALBO) and Frequency Therapeutics (FREQ)December 12, 2022 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Sutro Biopharma (STRO)December 3, 2022 | seekingalpha.comAllogene: Pioneering Allogeneic CAR-T Developer With No Near-Term CatalystsNovember 22, 2022 | finance.yahoo.comWall Street Analysts Believe Allogene Therapeutics (ALLO) Could Rally 137%: Here's is How to TradeNovember 9, 2022 | markets.businessinsider.comJMP Securities Keeps Their Buy Rating on Bicycle Therapeutics (BCYC)November 8, 2022 | markets.businessinsider.comJMP Securities Reaffirms Their Buy Rating on BioAtla (BCAB)November 3, 2022 | finance.yahoo.comAllogene Therapeutics Announces Poster Presentation of Its Phase 1 UNIVERSAL Trial in Multiple Myeloma at the 64th Annual Meeting of the American Society of HematologyNovember 2, 2022 | finance.yahoo.comAllogene Therapeutics Reports Third Quarter 2022 Financial Results and Announces Investor R&D ShowcaseOctober 31, 2022 | finance.yahoo.comAllogene Overland Biopharm Completes Buildout of cGMP Manufacturing Facility in Shanghai to Support the Development of AlloCAR T™ Products in AsiaOctober 26, 2022 | finance.yahoo.comAllogene Therapeutics to Report Third Quarter 2022 Financial Results on November 2, 2022October 12, 2022 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Mersana Therapeutics (MRSN) and Allogene Therapeutics (ALLO)See More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive ALLO Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Allogene Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ALLO Company Calendar Last Earnings11/04/2021Today2/08/2023Next Earnings (Estimated)2/22/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Biological products, except diagnostic Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:ALLO CUSIPN/A CIK1737287 Webwww.allogene.com Phone(650) 457-2700FaxN/AEmployees308Year Founded2018Price Target and Rating Average Stock Price Forecast$20.27 High Stock Price Forecast$32.00 Low Stock Price Forecast$9.00 Forecasted Upside/Downside+181.6%Consensus RatingModerate Buy Rating Score (0-4)2.73 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($2.20) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-257,010,000.00 Net Margins-126,580.16% Pretax Margin-126,580.18% Return on Equity-37.74% Return on Assets-32.58% Debt Debt-to-Equity RatioN/A Current Ratio11.64 Quick Ratio11.64 Sales & Book Value Annual Sales$38.49 million Price / Sales26.98 Cash FlowN/A Price / Cash FlowN/A Book Value$6.43 per share Price / Book1.12Miscellaneous Outstanding Shares144,210,000Free Float101,235,000Market Cap$1.04 billion OptionableNot Optionable Beta0.77 Social Links Key ExecutivesDavid D. ChangPresident, Chief Executive Officer & DirectorEric SchmidtChief Financial OfficerBarbra SasuChief Scientific OfficerAlison MooreChief Technical OfficerArun BalakumaranChief Medical OfficerKey CompetitorsInhibrxNASDAQ:INBXIovance BiotherapeuticsNASDAQ:IOVAREGENXBIONASDAQ:RGNXExscientiaNASDAQ:EXAIVericelNASDAQ:VCELView All CompetitorsInsiders & InstitutionsNordea Investment Management ABSold 11,487 shares on 2/8/2023Ownership: 0.453%Thrivent Financial for LutheransBought 290,286 shares on 2/8/2023Ownership: 0.317%Coastal Bridge Advisors LLCBought 7,418 shares on 2/8/2023Ownership: 0.282%Swiss National BankBought 4,100 shares on 2/8/2023Ownership: 0.145%UBS Group AGSold 45,596 shares on 2/8/2023Ownership: 0.094%View All Insider TransactionsView All Institutional Transactions ALLO Stock - Frequently Asked Questions Should I buy or sell Allogene Therapeutics stock right now? 11 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Allogene Therapeutics in the last twelve months. There are currently 1 sell rating, 1 hold rating and 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" ALLO shares. View ALLO analyst ratings or view top-rated stocks. What is Allogene Therapeutics' stock price forecast for 2023? 11 Wall Street research analysts have issued 12-month target prices for Allogene Therapeutics' shares. Their ALLO share price forecasts range from $9.00 to $32.00. On average, they anticipate the company's stock price to reach $20.27 in the next twelve months. This suggests a possible upside of 181.6% from the stock's current price. View analysts price targets for ALLO or view top-rated stocks among Wall Street analysts. How have ALLO shares performed in 2023? Allogene Therapeutics' stock was trading at $6.29 at the beginning of 2023. Since then, ALLO shares have increased by 14.5% and is now trading at $7.20. View the best growth stocks for 2023 here. When is Allogene Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, February 22nd 2023. View our ALLO earnings forecast. How were Allogene Therapeutics' earnings last quarter? Allogene Therapeutics, Inc. (NASDAQ:ALLO) announced its earnings results on Thursday, November, 4th. The company reported ($0.57) earnings per share for the quarter, missing analysts' consensus estimates of ($0.56) by $0.01. The business earned $0.05 million during the quarter. Allogene Therapeutics had a negative trailing twelve-month return on equity of 37.74% and a negative net margin of 126,580.16%. During the same period last year, the business earned ($0.52) earnings per share. What is David Chang's approval rating as Allogene Therapeutics' CEO? 2 employees have rated Allogene Therapeutics Chief Executive Officer David Chang on Glassdoor.com. David Chang has an approval rating of 100% among the company's employees. This puts David Chang in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. What other stocks do shareholders of Allogene Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Allogene Therapeutics investors own include NVIDIA (NVDA), Advanced Micro Devices (AMD), Gilead Sciences (GILD), Inovio Pharmaceuticals (INO), Pfizer (PFE), Teladoc Health (TDOC), AbbVie (ABBV), Alibaba Group (BABA), Bristol-Myers Squibb (BMY) and CRISPR Therapeutics (CRSP). When did Allogene Therapeutics IPO? (ALLO) raised $272 million in an initial public offering (IPO) on Thursday, October 11th 2018. The company issued 16,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, Cowen and Jefferies acted as the underwriters for the IPO. What is Allogene Therapeutics' stock symbol? Allogene Therapeutics trades on the NASDAQ under the ticker symbol "ALLO." Who are Allogene Therapeutics' major shareholders? Allogene Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional investors include Nordea Investment Management AB (0.45%), Thrivent Financial for Lutherans (0.32%), Coastal Bridge Advisors LLC (0.28%), Swiss National Bank (0.14%), TD Asset Management Inc (0.12%) and Mitsubishi UFJ Kokusai Asset Management Co. Ltd. (0.11%). Insiders that own company stock include Alison Moore, Arie Belldegrun, David D Chang, Eric Thomas Schmidt, Group Holdings (Sbs) Advis Tpg, Owen N Witte, Owen N Witte, Rafael Amado and Veer Bhavnagri. View institutional ownership trends. How do I buy shares of Allogene Therapeutics? Shares of ALLO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Allogene Therapeutics' stock price today? One share of ALLO stock can currently be purchased for approximately $7.20. How much money does Allogene Therapeutics make? Allogene Therapeutics (NASDAQ:ALLO) has a market capitalization of $1.04 billion and generates $38.49 million in revenue each year. The company earns $-257,010,000.00 in net income (profit) each year or ($2.20) on an earnings per share basis. How many employees does Allogene Therapeutics have? The company employs 308 workers across the globe. How can I contact Allogene Therapeutics? Allogene Therapeutics' mailing address is 210 EAST GRAND AVENUE, SOUTH SAN FRANCISCO CA, 94080. The official website for the company is www.allogene.com. The company can be reached via phone at (650) 457-2700 or via email at ir@allogene.com. This page (NASDAQ:ALLO) was last updated on 2/8/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.